<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394105</url>
  </required_header>
  <id_info>
    <org_study_id>C2015-00353_Pleurodesis</org_study_id>
    <nct_id>NCT03394105</nct_id>
  </id_info>
  <brief_title>Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer</brief_title>
  <official_title>Pilot Study to Evaluate the Effect of Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, the effect of intrapleural docetaxel administration using medical
      pleuroscopywill be evaluated in Lung Cancer patient with malignant effusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to be pilot, single-center, open-label, single-arm, prospective, phase
      II trial of patient with NSCLC with pleurla effusion. Approximately 40 patients will be
      enrolled into the trial, and study will be performed to 31Dec2018 from IRB and Korea: MFDS
      approval date.

      Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant
      effusion with lung cancer. Response evaluation will be done until confiramtion of disease
      progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall respose rate(ORR)</measure>
    <time_frame>through study completion (2.5 years)</time_frame>
    <description>Rate of CR and PR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete resonse (CR) rate</measure>
    <time_frame>through study completion (2.5 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression(TTP)</measure>
    <time_frame>through study completion (2.5 years)</time_frame>
    <description>time from the date of the start of treatment until the disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>through study completion (2.5 years)</time_frame>
    <description>time fromthe date of the start of treatment to death or the date of last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>through study completion (2.5 years)</time_frame>
    <description>Based on National Cancer Institute Common Toxicity Criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pleural Effusion, Malignant</condition>
  <condition>Non-small Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>intrapleural docetaxel administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intrapleural docetaxel administration</intervention_name>
    <description>intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer</description>
    <arm_group_label>intrapleural docetaxel administration</arm_group_label>
    <other_name>Pleurodesis_docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 20, and NSCLC patients with malignant pleural effusion and related symptoms

          -  ECOG ≤ 2

          -  Blood test ANC≥ 1500/mm3, Hb ≥ 8.0g/dl, platelet count ≥ 100000/mm3 Serum creatinine ≤
             1.8mg/dl, Total bilirubin within normal limits, Transaminases ≤ 1.5 x UNL, Alkaline
             phosphatase ≤ 2.5 X UNL BUN ≤ 25mg/dl, Creatinine clearance ≥ 50ml/min

          -  Negative serum or urine pregnancy test for women for childbearing age

          -  Patients who provide written informed consent for the study

        Exclusion Criteria:

          -  Age &lt; 20

          -  Patients who were previously perfomed pleurodesis

          -  Patients who were previously treated with thoracic radiosurgery

          -  Patinet with bilateral pleural effusion

          -  Age ≥ 80yrs

          -  Patients with histories of hypersensitivity to Docetaxel

          -  Patients with cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             neunological disease, asthma, MI, stroke, arrhythmia, uncontrolled hypertionsion, etc.
             that would effect absorption, distribution, and metabolism of IP or be risk factors
             during IP administrion.

          -  Patients who could not understand the study procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHANG-MIN CHOI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CHANG-MIN CHOI, MD, PhD</last_name>
    <phone>+82-2-3010-5902</phone>
    <email>Chang-Min Choi &lt;ccm9607@gmail.com&gt;</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHANG-MIN CHOI, PhD</last_name>
      <phone>+82-2-3010-5902</phone>
      <email>ccm9607@gmail.com</email>
    </contact>
    <investigator>
      <last_name>CHANG-MIN CHOI, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Chang-Min Choi</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>Pleurodesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

